KLF4 initiates sustained YAP activation to promote renal fibrosis in mice after ischemia-reperfusion kidney injury
Tóm tắt
Từ khóa
Tài liệu tham khảo
Vanmassenhove J, Van Biesen W, Vanholder R, Lameire N. Subclinical AKI: ready for primetime in clinical practice? J Nephrol. 2019;32:9–16.
Parikh CR, Mansour SG. Perspective on clinical application of biomarkers in AKI. J Am Soc Nephrol. 2017;28:1677–85.
See EJ, Jayasinghe K, Glassford N, Bailey M, Johnson DW, Polkinghorne KR, et al. Long-term risk of adverse outcomes after acute kidney injury: a systematic review and meta-analysis of cohort studies using consensus definitions of exposure. Kidney Int. 2019;95:160–72.
Coca SG, Singanamala S, Parikh CR. Chronic kidney disease after acute kidney injury: a systematic review and meta-analysis. Kidney Int. 2012;81:442–8.
Xu D, Wang B, Chen P, Wang YZ, Miao NJ, Yin F, et al. c-Myc promotes tubular cell apoptosis in ischemia-reperfusion-induced renal injury by negatively regulating c-FLIP and enhancing FasL/Fas-mediated apoptosis pathway. Acta Pharmacol Sin. 2019;40:1058–66.
Srisawat N, Murugan R, Kellum JA. Repair or progression after AKI: a role for biomarkers? Nephron Clin Pr. 2014;127:185–89.
Ferenbach DA, Bonventre JV. Mechanisms of maladaptive repair after AKI leading to accelerated kidney ageing and CKD. Nat Rev Nephrol. 2015;11:264–76.
Chatauret N, Badet L, Barrou B, Hauet T. Ischemia-reperfusion: from cell biology to acute kidney injury. Prog Urol. 2014;24(Suppl 1):S4–12.
Bonventre JV. Primary proximal tubule injury leads to epithelial cell cycle arrest, fibrosis, vascular rarefaction, and glomerulosclerosis. Kidney Int Suppl (2011). 2014;4:39–44.
Tanaka S, Tanaka T, Nangaku M. Hypoxia as a key player in the AKI-to-CKD transition. Am J Physiol Ren Physiol. 2014;307:F1187–95.
Bonventre JV. Maladaptive proximal tubule repair: cell cycle arrest. Nephron Clin Pract. 2014;127:61–4.
Goldstein SL, Jaber BL, Faubel S, Chawla LS. AKI transition of care: a potential opportunity to detect and prevent CKD. Clin J Am Soc Nephrol. 2013;8:476–83.
Basile DP, Bonventre JV, Mehta R, Nangaku M, Unwin R, Rosner MH, et al. Progression after AKI: understanding maladaptive repair processes to predict and identify therapeutic treatments. J Am Soc Nephrol. 2016;27:687–97.
Humphreys BD, Cantaluppi V, Portilla D, Singbartl K, Yang L, Rosner MH, et al. Targeting endogenous repair pathways after AKI. J Am Soc Nephrol. 2016;27:990–8.
Maas K, Mirabal S, Penzias A, Sweetnam PM, Eggan KC, Sakkas D. Hippo signaling in the ovary and polycystic ovarian syndrome. J Assist Reprod Genet. 2018;35:1763–71.
Frum T, Murphy TM, Ralston A. HIPPO signaling resolves embryonic cell fate conflicts during establishment of pluripotency in vivo. Elife. 2018;7:e42298. https://doi.org/10.7554/eLife.42298.
5Volckaert T, Yuan T, Yuan J, Boateng E, Hopkins S, Zhang JS, et al. Hippo signaling promotes lung epithelial lineage commitment by curbing Fgf10 and beta-catenin signaling. Development. 2019;146:dev166454. https://doi.org/10.1242/dev.166454.
Nair PR, Wirtz D. Enabling migration by moderation: YAP/TAZ are essential for persistent migration. J Cell Biol. 2019;218:1092–3.
Han H, Yang B, Nakaoka HJ, Yang J, Zhao Y, Le Nguyen K, et al. Hippo signaling dysfunction induces cancer cell addiction to YAP. Oncogene. 2018;37:6414–24.
Lian I, Kim J, Okazawa H, Zhao J, Zhao B, Yu J, et al. The role of YAP transcription coactivator in regulating stem cell self-renewal and differentiation. Genes Dev. 2010;24:1106–18.
White SM, Murakami S, Yi C. The complex entanglement of Hippo-Yap/Taz signaling in tumor immunity. Oncogene. 2019;38:2899–909.
Sugihara T, Isomoto H, Gores G, Smoot R. YAP and the hippo pathway in cholangiocarcinoma. J Gastroenterol. 2019;54:485–91.
Chen J, You H, Li Y, Xu Y, He Q, Harris RC. EGF receptor-dependent YAP activation is important for renal recovery from AKI. J Am Soc Nephrol. 2018;29:2372–85.
Sharma M, Radhakrishnan R. CTGF is obligatory for TGF-beta1 mediated fibrosis in OSMF. Oral Oncol. 2016;56:e10–11.
Li L, Dong L, Wang Y, Zhang X, Yan J. Lats1/2-mediated alteration of hippo signaling pathway regulates the fate of bone marrow-derived mesenchymal stem cells. Biomed Res Int. 2018;2018:4387932.
Nishioka N, Inoue K, Adachi K, Kiyonari H, Ota M, Ralston A, et al. The hippo signaling pathway components Lats and Yap pattern Tead4 activity to distinguish mouse trophectoderm from inner cell mass. Dev Cell. 2009;16:398–410.
Ho KC, Zhou Z, She YM, Chun A, Cyr TD, Yang X. Itch E3 ubiquitin ligase regulates large tumor suppressor 1 stability. Proc Natl Acad Sci USA. 2011;108:4870–5.
Marzi I, Cipolleschi MG, D’Amico M, Stivarou T, Rovida E, Vinci MC, et al. The involvement of a Nanog, Klf4 and c-Myc transcriptional circuitry in the intertwining between neoplastic progression and reprogramming. Cell Cycle. 2013;12:353–64.
Choi H, Roh J. Role of klf4 in the regulation of apoptosis and cell cycle in rat granulosa cells during the periovulatory period. Int J Mol Sci. 2018;20:87. https://doi.org/10.3390/ijms20010087.
Tang J, Zhong G, Wu J, Chen H, Jia Y. SOX2 recruits KLF4 to regulate nasopharyngeal carcinoma proliferation via PI3K/AKT signaling. Oncogenesis. 2018;7:61. https://doi.org/10.1038/s41389-018-0074-2.
Cheng Z, Zou X, Jin Y, Gao S, Lv J, Li B, et al. The role of KLF4 in Alzheimer's disease. Front Cell Neurosci. 2018;12:325. https://doi.org/10.3389/fncel.2018.00325.
Brauer PR, Kim JH, Ochoa HJ, Stratton ER, Black KM, Rosencrans W, et al. Kruppel-like factor 4 mediates cellular migration and invasion by altering RhoA activity. Cell Commun Adhes. 2018;24:1–10.
Qi XT, Li YL, Zhang YQ, Xu T, Lu B, Fang L, et al. KLF4 functions as an oncogene in promoting cancer stem cell-like characteristics in osteosarcoma cells. Acta Pharmacol Sin. 2019;40:546–55.
Shen Y, Miao N, Wang B, Xu J, Gan X, Xu D, et al. c-Myc promotes renal fibrosis by inducing integrin alphav-mediated transforming growth factor-beta signaling. Kidney Int. 2017;92:888–99.
Pan Y, Alegot H, Rauskolb C, Irvine KD. The dynamics of Hippo signaling during Drosophila wing development. Development. 2018;145:dev165712. https://doi.org/10.1242/dev.165712.
Xu D, Chen P, Wang B, Wang Y, Miao N, Yin F, et al. NIX-mediated mitophagy protects against proteinuria-induced tubular cell apoptosis and renal injury. Am J Physiol Renal Physiol. 2019;316:F382–95.
Bernhardt A, Fehr A, Brandt S, Jerchel S, Ballhause TM, Philipsen L, et al. Inflammatory cell infiltration and resolution of kidney inflammation is orchestrated by the cold-shock protein Y-box binding protein-1. Kidney Int. 2017;92:1157–77.
Fu Y, Tang C, Cai J, Chen G, Zhang D, Dong Z. Rodent models of AKI-CKD transition. Am J Physiol-Ren. 2018;315:F1098–106.
Luo C, Zhou S, Zhou Z, Liu Y, Yang L, Liu J, et al. Wnt9a promotes renal fibrosis by accelerating cellular senescence in tubular epithelial cells. J Am Soc Nephrol. 2018;29:1238–56.
Liu BC, Tang TT, Lv LL, Lan HY. Renal tubule injury: a driving force toward chronic kidney disease. Kidney Int. 2018;93:568–79.
Tan RJ, Zhou D, Liu Y. Signaling crosstalk between tubular epithelial cells and interstitial fibroblasts after kidney injury. Kidney Dis. 2016;2:136–44.
Szeto SG, Narimatsu M, Lu M, He X, Sidiqi AM, Tolosa MF, et al. YAP/TAZ are mechanoregulators of TGF-beta-Smad signaling and renal fibrogenesis. ed. 2016:3117–28.
Macconi D, Remuzzi G, Benigni A. Key fibrogenic mediators: old players. Renin-angiotensin system. Kidney Int Suppl (2011). 2014;4:58–64.
Ito Y, Aten J, Bende RJ, Oemar BS, Rabelink TJ, Weening JJ, et al. Expression of connective tissue growth factor in human renal fibrosis. Kidney Int. 1998;53:853–61.
Wolf G. Renal injury due to renin-angiotensin-aldosterone system activation of the transforming growth factor-beta pathway. Kidney Int. 2006;70:1914–9.
Zhou D, Li Y, Zhou L, Tan RJ, Xiao L, Liang M, et al. Sonic hedgehog is a novel tubule-derived growth factor for interstitial fibroblasts after kidney injury. J Am Soc Nephrol. 2014;25:2187–200.
Ding H, Zhou D, Hao S, Zhou L, He W, Nie J, et al. Sonic hedgehog signaling mediates epithelial-mesenchymal communication and promotes renal fibrosis. J Am Soc Nephrol. 2012;23:801–13.